Co-Delivery of 8-Hydroxyquinoline Glycoconjugates and Doxorubicin by Supramolecular Hydrogel Based on α-Cyclodextrin and pH-Responsive Micelles for Enhanced Tumor Treatment

Two birds with one stone:
This study of the Silesian University of Technology and the Polish Academy of Sciences is close to our hearts as we both deal with glycoconjugates and cyclodextrin. They show the delivery of 8-Hydroxyquinoline Glycoconjugates and Doxorubicin using ACD-based hydrogel for enhanced tumor treatment.

Monika D. Gabriela Pastuch Piotr Kurcok 

See the full article here

Molecular docking approach for prediction of enantioseparation of miconazole using cyclodextrin derivatives as chiral selector

I have spent several years studying the chiral recognition of CDs and always considered that selectivity is unpredictable and needs to be tested. In the paper of Jenderal Soedirman University (Ainaya Halwa Lathufa, Uyi Sulaeman, et al.) and Hassan Aboul-Enein enatioseparation of miconazole with molecular docking is predicted using CD derivatives such as sulfated-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, and hydroxypropyl-γ-cyclodextrin as chiral selectors.

See the full article here.

The problem is that all these CDs are composites consisting of hundreds of different specific molecules, which makes proper modeling, so to say, “challenging.” But what do you think?

If you want to vote, click on the link below!

https://www.linkedin.com/posts/tamassohajda_cyclodextrin-chiral-analyticalchemistry-activity-7001422316689608704–S6w?utm_source=share&utm_medium=member_desktop

Sugar-decorated carbon dots: a novel tool for targeting immunomodulatory receptor

Griffith University (Oren CooperDechao ChenThomas HaselhorstJoseph Tiralongo et al) and University of Bremen released common findings on creating multivalent siglec probes through the decoration of α(2,6)-sialyllactose ligands on inherently fluorescent carbon dots capable of generating a significant cytotoxic effect on Burkitt’s Lymphoma (BL) Daudi B cells.

See the full article here

Turbine Raises €20 Million in Series A Financing to Advance Programs & Partnerships Towards the Clinic with World’s First Cancer Cell Simulation Platform

Turbine Raises €20 Mn to Advance Its Cancer Cell Simulation Platform.
Turbine leverages its technology by identifying associated biomarkers and combination strategies and selecting in vitro and in vivo biological models for experimental validation. Turbine partners with biopharmaceutical companies seeking to deploy simulations to understand patients and overcome causes of resistance hindering drug development in the clinic. 

See the full article on BusinessWire

Weekly round-up of other carbohydrate-related articles (2022/47)

I.
Great review from Universidade de Coimbra (Ana Cláudia Paiva-SantosLaura FerreiraFilipa Mascarenhas MeloSofia RabaçaFrancisco Veiga), Mewar University (Dr. Ankita Mathur), Sharda UniversityUniversity at Buffalo (Dr. Prabhanjan Giram), Shivaji UniversityUniversity of Zabol (Abbas Rahdar), Shanghai Jiao Tong University (Faisal Raza 费赛), Faculdade de Ciências Farmacêuticas – Unicamp (ENG: Pharmacy School – University of Campinas) (Priscila Mazzola) on dermatology and cosmetic applications

Read the full article here

II.
Beta-Cyclodextrins as affordable antivirals to treat coronavirus infection

Read the full article here

III.
Honestly, I am not sure how mankind will handle medication related to space travel. That will be a huge challenge that needs to be studied asap. Recently, the interaction behavior of remdesivir with CDs was studied at ISS (pp 53)

See the NASA e-book here

IV.
How cool is it that you can use CDs to stabilize antigens? Super cool 🙂
Polypseudorotaxane hydrogels based on cyclodextrin and polyethylene glycol significantly improved the stability of antibody preparations and showed no serious adverse effects after subcutaneous injection, suggesting the possibility as safe vaccine formulations to stabilize an antigen protein.
Daiichi University of Pharmacy
Kumamoto University, JAPAN
Hiroshi Itou Hidetoshi Arima Keiichi Motoyama

Read the full article here

V.
Enrichment of bread with α-CD resulted in positive effects on postprandial glycaemia and induced satiety. The incorporation of encapsulated hydroxytyrosol offered similar overall acceptability due to the bitter taste-masking effect provided by α-CD and a slightly additional positive effect in postprandial glycaemia and satiety. The development of foods with favorable metabolic effects is of great importance for the prevention of chronic diseases. The study was prospectively registered in clinicaltrials.gov (NCT04725955, date: 27th January 2021).
Harokopio University of Athens – Panagiota BinouAthena StergiouNikolaos Tentolouris, Vaios K.

See the full article here

VI.
Is the humid autumn whether messing up your hair? Keep calm and use CD-formulations (L’Oréal invention – Cho-Cho Khine and Ronak Rughani) for providing lasting curl definition and/or frizz and/or volume control to hair, even in high humidity.

See the full patent here

Scientific collaboration with University of Turin

Our CSO, Milo Malanga PhD spent the last week at Università degli Studi di Torino in the lab of Francesco Trotta, supporting students in their chemistry visions and creating nanosponges together as well as delivering a scientific seminar on the uses of cyclodextrin in biotechnology. We will explore together the potential uses of the created compounds as novel drug delivery systems in the coming months. Next year CarboHyde will host students from the Trotta lab to continue the synthetic work and create new compounds supporting our collaborative R&D program.

Dibenzocyclooctyne linked lysine-cyclodextrin for efficient intranucleus delivery of proteins

Now, this is something we have never seen before. Delivering oligonucleotides into cells using cyclodextrin-based nanoparticles has been studied a lot, yet in the paper from Chongqing University, intranucleus delivery of proteins is shown. This will certainly open up new drug delivery possibilities for the future and trigger novel applications.

Read the full article on ScienceDirect

In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe’s Disease

Amazing therapeutic success led by UCSF Pediatrics joined by Duke UniversityOttawa University, and Washington University via in-utero enzyme-replacement therapy for infantile-onset Pompe’s disease: Patients with early-onset lysosomal storage diseases are ideal candidates for prenatal therapy because organ damage starts in utero. After receiving in-utero ERT and standard postnatal therapy, the current patient had normal cardiac and age-appropriate motor function postnatally, was meeting developmental milestones, had normal biomarker levels, and was feeding and growing well at 13 months of age.

See the full article here